Gemina Laboratories Ltd
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporat… Read more
Market Cap & Net Worth: Gemina Laboratories Ltd (GLABF)
Gemina Laboratories Ltd (OTCQB:GLABF) has a market capitalization of $60.13 Million ($60.13 Million) as of March 19, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #22993 globally and #8076 in its home market, demonstrating a -10.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gemina Laboratories Ltd's stock price $0.79 by its total outstanding shares 76570896 (76.57 Million).
Gemina Laboratories Ltd Market Cap History: 2022 to 2025
Gemina Laboratories Ltd's market capitalization history from 2022 to 2025. Data shows growth from $16.74 Million to $60.13 Million (23.06% CAGR).
Gemina Laboratories Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gemina Laboratories Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
-4783.04x
Gemina Laboratories Ltd's market cap is -4783.04 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $26.03 Million | $-5.44K | -$5.98 Million | -4783.04x | N/A |
Competitor Companies of GLABF by Market Capitalization
Companies near Gemina Laboratories Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Gemina Laboratories Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Gemina Laboratories Ltd Historical Marketcap From 2022 to 2025
Between 2022 and today, Gemina Laboratories Ltd's market cap moved from $16.74 Million to $ 60.13 Million, with a yearly change of 23.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $60.13 Million | +42.78% |
| 2024 | $42.11 Million | +61.76% |
| 2023 | $26.03 Million | +55.54% |
| 2022 | $16.74 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Gemina Laboratories Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $60.13 Million USD |
| MoneyControl | $60.13 Million USD |
| MarketWatch | $60.13 Million USD |
| marketcap.company | $60.13 Million USD |
| Reuters | $60.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.